

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Canceled)

2. (Currently Amended) A method for the treatment of an immune-related or immune-mediated disorder[[s]] or disease[[s]] in a mammalian subject in need of such treatment, the method comprising ~~manipulating the NKT cell population of said subject, wherein manipulation of said NKT cell population results in modulation of the Th1/Th2 cell balance towards an anti-inflammatory response, said modulation being mediated by~~

(a) obtaining NKT cells from said mammalian subject or another subject;

(b) ex vivo educating the NKT cells; and

(c) re-introducing to said subject the educated NKT cells obtained in step (b),

wherein the NKT cells are educated by culturing the cells in the presence of

(a') proteins extracted from homogenized tissue of the type affected by the immune-related disorder or disease,

(b') at least one liver-associated CD4+ or CD8+ lymphocyte cell of a tolerized or non-tolerized subject suffering from said immune-related or immune-mediated disorder or of said mammalian subject, or

(c') a combination of (a') and (b'); thereof

wherein the immune-related or immune-mediated disorder or disease is autoimmune liver disease, inflammatory bowel disease, Crohn's disease, graft vs. host disease, graft vs. host-associated liver disease, obesity, diabetes mellitus, metabolic syndrome, glucose intolerance, or non-alcoholic steatohepatitis.

3-8. (Canceled)

9. (Currently Amended) The method of claim 2[[7]], ~~wherein the NKT cells are cultured in the presence of the proteins, wherein said proteins~~ homogenized tissue comprises allogeneic antigens, xenogenic antigens, syngeneic antigens, or autologous antigens.

10. (Currently Amended) The method of claim 2[[7]], wherein said NKT cells are further cultured in the presence of at least one cytokine, the adhesion molecule selectin, or any combination thereof.

11. (Previously Presented) The method of claim 10, wherein said NKT cells are further cultured in the presence of at least one cytokine.

12-24. (Canceled)

25. (Withdrawn/Currently Amended) The method of ~~any one of claims 1 to 2[[4]]~~, wherein said immune-related or immune-mediated disorder or disease is Non-Alcoholic Steatohepatitis.

26. (Withdrawn/Currently Amended) The method of ~~any one of claims 1 to 2[[4]]~~, wherein said immune-related or immune-mediated disorder or disease is diabetes mellitus or glucose intolerance.

27. (Withdrawn/Currently Amended) The method of ~~any one of claims 1 to 2[[4]]~~, wherein said immune-related or immune-mediated disorder or disease is obesity.

28. (Withdrawn/Currently Amended) The method of ~~any one of claims 1 to 2[[4]]~~, wherein said immune-related or immune-mediated disorder or disease is metabolic syndrome.

29. (Withdrawn/Currently Amended) The method of ~~any one of claims 1 to 2~~[[4]], wherein said immune-related or immune-mediated disorder or disease is Graft Versus Host Disease.

30. (Canceled)

31. (Currently Amended) The method of claim 2 ~~or 3~~, wherein said mammalian subject is a human patient.

32. (Previously Presented) The method of claim 31, wherein said NKT cells are NKT cells expressing the CD56 marker.

33-170. (Canceled)

171. (Currently Amended) The method of claim 2[[6]], further comprising orally administering the ~~proteins~~ homogenized tissue to the subject.

172. (Currently Amended) The method of claim 2[[or 3]], wherein said tissue is healthy tissue.

173. (Currently Amended) The method of claim 2[[or 3]], wherein said tissue is tissue diseased from the immune-related or immune-mediated disorder or disease.

174-176. (Canceled)

177. (Withdrawn) The method of claim 10, wherein said NKT cells are further cultured in the presence of selectin.

178. (Previously Presented) The method of claim 10, wherein said NKT cells are further cultured in the presence of at least one cytokine.

179. (Previously Presented) The method of claim 178, wherein the at least one cytokine is IL4, IL10, TGF β or IL2.

180. (Previously Presented) The method of claim 178, wherein the at least one cytokine is IL4 or IL10.

181. (Previously Presented) The method of claim 178, wherein the at least one cytokine is IL4.

182. (Currently Amended) The method according to claim 2[[or 3]], wherein said immune-related or immune-mediated disorder or disease comprises inflammatory bowel disease, Crohn's disease, graft vs. host disease, graft vs. host-associated liver disease, or non-alcoholic steatohepatitis.

183. (Currently Amended) The method according to claim 2[[or 3]], wherein said immune-related or immune-mediated disorder or disease comprises inflammatory bowel disease.

184. (Currently Amended) The method according to claim 2[[or 3]], wherein said immune-related or immune-mediated disorder or disease comprises Crohn's disease.

185. (Withdrawn/Currently Amended) The method according to claim 2[[or 3]], wherein said immune-related or immune-mediated disorder or disease comprises graft vs. host-associated liver disease.

186. (Withdrawn/Currently Amended) The method according to claim 2[[or 3]], wherein said immune-related or immune-mediated disorder or disease comprises non-alcoholic steatohepatitis.

187. (New/Withdrawn) The method of claim 2, wherein said homogenized tissue comprises autologous antigens.